Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: Results from two phase 2 studies
British Journal of Dermatology — Alavi A, Hamzavi I, Brown K, et al. | January 05, 2022
Analyzing two multicenter phase 2 trials of the Janus kinase (JAK) 1 inhibitor INCB054707 in patients with moderate-to-severe hidradenitis suppurativa (HS), it was found that INCB054707 showed good tolerability and induced responses in patients with moderate-to-severe HS. Safety and efficacy results from these studies demonstrate proof of concept for JAK1 inhibition in HS.
Eligible patients with moderate-to-severe HS were administered open-label 15 mg INCB054707 once daily (QD; Study 1) or were randomly assigned to 30, 60, or 90 mg INCB054707 QD or placebo (3:1 within each cohort; Study 2) for 8 weeks.
Occurrence of ≥1 treatment-emergent adverse event (TEAE) was evident in 70·0% and 80·8% of patients in Study 1 and Study 2, respectively, who were treated with INCB054707; 30·0% and 42·3% of patients, respectively, suffered ≥1 treatment-related TEAE.
Of evaluable cases, HiSCR (HS Clinical Response) at Week 8 was achieved in 3 patients (42∙9%) in Study 1 and 17 patients (overall 65·4%: 30 mg, 55·6%; 60 mg, 55·6%; 90 mg, 87·5%) taking INCB054707 vs 4 patients (57·1%) on placebo in Study 2.